442851-50-5

Basic information

• Product Name: Atorvastatin Dehydro Lactone
• Synonyms: Atorvastatin Dehydro Lactone;3-Dehydroxy 2,3-Dehydro Atorvastatin Lactone;2,3-Anhydro Atorvastatin Lactone
• CAS NO: 442851-50-5
• Molecular Formula: C₃₃H₃₁FN₂O₃
• Molecular Weight: 522.6092432
• Mol File: 442851-50-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Atorvastatin Dehydro Lactone(CAS DataBase Reference)
• NIST Chemistry Reference: Atorvastatin Dehydro Lactone(442851-50-5)
• EPA Substance Registry System: Atorvastatin Dehydro Lactone(442851-50-5)

Safety Data

• Hazardous Substances Data: 442851-50-5(Hazardous Substances Data)

Usage

Description

Atorvastatin Dehydro Lactone is an intermediate compound in the synthesis of Atorvastatin (A791750) and its derivatives. It plays a crucial role in the production process of Atorvastatin, a widely used cholesterol-lowering drug.
Used in Pharmaceutical Industry:
Atorvastatin Dehydro Lactone is used as a key intermediate in the synthesis of Atorvastatin for the treatment of hypercholesterolemia. It helps in the production of the final drug, which is effective in reducing low-density lipoprotein (LDL) cholesterol levels and managing cardiovascular diseases.
Used in Research and Development:
Atorvastatin Dehydro Lactone is also used as a research compound for the development of new drugs and pharmaceutical formulations. It serves as a valuable tool for scientists and researchers to study the properties and mechanisms of Atorvastatin and its derivatives, leading to the discovery of novel therapeutic agents.

Upstream product

• 134523-03-8 lipitor 

Relevant articles and documents

Characterization of two new degradation products of atorvastatin calcium formed upon treatment with strong acids

Atorvastatin calcium (Lipitor, Sortis) is a well-established cholesterol synthesis enzyme (CSE) inhibitor commonly used in the therapy of hypercholesterolemia. This drug is known to be sensitive to acid treatment, but only little data has been published on the structures of the degradation products. Here we report the identification of two novel degradation products of atorvastatin, which are formed only under drastic acidic conditions. While treatment with conc. sulfuric acid led to a loss of the carboxanilide residue (accompanied by an expectable lactonization/dehydration process in the side chain), treatment with conc. aqueous hydrochloric acid gave a complex, bridged molecule under C–C-bond formation of the lactone moiety with the pyrrole, migration of the isopropyl group and loss of the carboxanilide residue. The novel degradation products were characterized by NMR spectroscopy, HRMS data and X-ray crystal structure analysis.

NOVEL PROCESS FOR THE SYNTHESIS OF 5-(4-FLUOROPHENYL)-1-[2-((2R,4R)-4-HYDROXY-6-OXO-TETRAHYDRO-PYRAN-2-YL)-ETHYL]-2-ISOPROPYL-4-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID PHENYLAMIDE

An improved process for the preparation of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide by a novel synthesis is described where methyl cyanoacetate is converted in eight operations or fewer to the desired product, as well as other valuable intermediates used in the process.